A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
AIDS Dementia ComplexHIV Infections
Interventions
DRUG

Abacavir sulfate

Trial Locations (9)

10029

Mount Sinai Med Ctr, New York

10032

Columbia Univ / Sergievsky Ctr, New York

21287

Johns Hopkins Univ School of Medicine, Baltimore

27599

Univ of North Carolina School of Medicine, Chapel Hill

63110

Washington Univ Med Ctr, St Louis

92103

HIV Neurobehavioral Research Ctr, San Diego

94110

San Francisco Gen Hosp, San Francisco

Unknown

Univ of Manitoba / Faculty of Medicine, Winnipeg

Wellesley Hosp, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002163 - A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex | Biotech Hunter | Biotech Hunter